65 results about "Lipoprotein cholesterol" patented technology

This invention discloses a low-astringency prickly pear lactic acid bacteria fermented beverage and its application in lowering blood lipids and antioxidation, relating to the fields of microbial application and food fermentation technology. The fermented beverage of this invention uses prickly pear juice as raw material and is prepared by fermentation with *Lactobacillus plantarum* R-21. It can significantly reduce the tannin content of prickly pear juice, improve taste, and increase the polysaccharide content and antioxidant properties of the beverage. In vivo experiments show that it can reduce the levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in mouse liver and serum, inhibit fat accumulation and fatty degeneration in liver cells, and enhance the activity of antioxidant enzymes in the liver, demonstrating important application value in lowering blood lipids and antioxidation.

The invention relates to application of an asparagine endopeptidase inhibitor in preparation of a medicine for improving insulin resistance. According to the application, starting from inhibiting the aging driving factor AEP, the AEP inhibitor is tried to be applied to the research of insulin resistance for the first time, and the AEP inhibitor is found to be capable of remarkably improving glucose tolerance and insulin sensitivity. Therefore, the invention provides the application of the asparagine endopeptidase inhibitor in preparation of the medicine for improving insulin resistance. Experiments prove that the AEP inhibitor not only can significantly enhance insulin sensitivity of old mice and improve glucose tolerance, but also can reduce serum low-density lipoprotein cholesterol and lactic dehydrogenase levels, shows multiple improvement effects on glucose metabolism and lipid metabolism, and also can be used for preparing the AEP inhibitor. After long-term administration, obvious toxic and side effects are not found in pathological examinations of blood routine examination, urine routine examination, heart, liver, spleen, lung, kidney and other important organs, so that the traditional Chinese medicine composition is proved to have good safety and is suitable for long-term intervention of chronic diseases.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, for reducing cholesterol, in particular total cholesterol (TC) and low-density lipoprotein cholesterol (LDL cholesterol). The invention also relates to dapiglutide for treatment of hyperlipidaemia, in particular hypercholesterolaemia.

The invention discloses application of a group of blood nutrition markers in prediction of central nervous system (CNS) injury function prognosis. According to the technical scheme, the method is characterized in that serum albumin, total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) are determined as independent predictive factors of CNS injury prognosis for the first time through retrospective queue research (n = 404), and clinical decision critical values are determined to be 36.35 g / L, 3.60 mmol / L and 2.13 mmol / L respectively. The detection kit developed on the basis of the discovery can objectively and quantitatively evaluate the prognosis risk of the patient within 24 hours of admission, and is obviously superior to that of a traditional scoring system. According to the method, key technical support is provided for precise nutrition intervention and early rehabilitation strategy formulation of the CNS injury.

The invention belongs to the technical field of functional compositions, and discloses a composition for dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof, and the composition comprises the following raw materials in percentage by mass: 13-28% of ginseng, 18-28% of globe artichoke, 10-27% of pueraria peptide, 7-12% of houttuynia cordata, 7-9% of mulberry, 6-9% of gardenia and 10-29% of collagen composite peptide. The composition can reduce alcohol irritation, relieve alcohol absorption and increase the alcohol content; meanwhile, the liver and stomach are protected; meanwhile, alcohol metabolism is rapid, hangover is prevented, headache, dizziness, nausea and other uncomfortable symptoms caused by alcohol are relieved, and the drunkenness degree is relieved. After the medicine is taken for 2-6 months, mild fatty liver and moderate fatty liver can be obviously improved, and severe fatty liver and alcoholic liver can be obviously improved; indexes related to endocrine metabolism, such as blood sugar, blood fat, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, are obviously improved.

The disclosure provides methods of treating heterozygous familial hypercholesterolemia (HeFH) and / or atherosclerotic cardiovascular disease (ASCVD), more particularly in subjects who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

The invention discloses a preparation method of torreya grandis gel candies with an effect of reducing total cholesterol. The invention belongs to the technical field of functional food, the Chinese torreya oil and the flaxseed oil have a synergistic effect, and after the Chinese torreya oil and the flaxseed oil are compounded, the blood fat metabolism can be effectively regulated, the total cholesterol level can be reduced, and the content of high-density lipoprotein cholesterol can be increased; the Chinese torreya oil is extracted through a low-temperature pressing process, the linseed oil is prepared through a cold pressing process, active components in the raw materials are reserved to the maximum extent, and meanwhile, the stability and uniformity of functional components in the product are ensured by combining a feeding pump filtering process and a rolling die shaping process; by optimizing the formula and the preparation process of the gel matrix, the product has good elasticity and chewing feeling, is convenient to carry and take and is suitable for daily use. The health-care food does not contain artificially synthesized additives, all the raw materials are natural sources, and the health-care food is suitable for patients with hypercholesterolemia and crowds needing to regulate blood fat, and has relatively high safety and market promotion value.

This invention discloses a *Lactobacillus plantarum* YBE2 and its applications. The *Lactobacillus plantarum* provided by this invention, which produces a high amount of extracellular polysaccharides primarily composed of rhamnose, can simultaneously degrade different types of bile salts, including specifically hydrolyzing glycocholic acid. It also exhibits cholesterol-lowering and acute inflammation-relieving effects. Furthermore, *Lactobacillus plantarum* YBE2 can reduce fat deposition in the abdomen of caged broilers, increase intramuscular fat, promote fatty acid deposition in muscles, and reduce plasma total bile acids, triglycerides, and low-density lipoprotein cholesterol. This significantly improves lipid metabolism and muscle quality in poultry, and can be widely applied in caged broiler farming to promote healthy poultry farming and improve farming efficiency.

The invention relates to a quality control liquid for low-density lipoprotein cholesterol and a preparation method of the quality control liquid. The quality control liquid comprises the following components in percentage by weight: 90-95% of defatted bovine serum, 0.005-0.05% of a cholesterol solution purified by ultracentrifugation, 1-3% of trehalose, 0.2-0.4% of EDTA-2K, 0.02-0.05% of vitamin E, 0.08-0.12% of a liquid biological preservative and 0.1-0.2% of glutathione. The invention has the following beneficial effects: 1, trehalose and vitamin E have a synergistic effect, and the stability at normal temperature reaches more than 12 months (CV is less than 3%); 2, a direct detection method, a precipitation method and a calculation method are adapted, and the deviation with a clinical sample is less than 5%; 3, the synthetic matrix reduces the risk of biogenic pollution, and is suitable for an automatic detection platform.

The invention discloses a roxburgh rose lactic acid bacteria solid beverage and application thereof in preparation of foods, health-care products or medicines for reducing hyperlipidemia, preventing colitis and resisting oxidation, and belongs to the field of probiotic health-care foods. The rosa roxburghii tratt lactic acid bacteria solid beverage is prepared from plant lactobacillus R-15, rosa roxburghii tratt fine powder, mannan oligosaccharide, resistant dextrin, coix lacryma-jobi extract, hawthorn extract, silicon dioxide and the like. The rosa roxburghii tratt lactobacillus solid beverage can significantly reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in the liver and serum of a mouse, inhibit fatty degeneration of the liver, and inhibit colitis induced by high fat diet. The invention has important application value in prevention and treatment of hyperlipidemia and colitis.

This invention relates to a traditional Chinese medicine composition, specifically a traditional Chinese medicine composition for treating diabetic nephropathy, belonging to the fields of medicine and health products. The traditional Chinese medicine composition of this invention is made from components comprising the following raw materials: yam, salvia miltiorrhiza, rosehip, turtle shell, cornus officinalis, dioscorea hypoglauca, cuscuta chinensis, oyster shell, and American ginseng. Through rational formulation, this traditional Chinese medicine composition utilizes the principle of clearing heat and removing dampness, with the synergistic effect of multiple drugs, to significantly reduce fasting blood glucose, improve glucose metabolism, lower low-density lipoprotein cholesterol and triglycerides, and raise high-density lipoprotein cholesterol to regulate lipid metabolism, reduce weight, and has no significant damage to liver and kidney function, with minimal side effects.

The application belongs to the technical field of biological medicine, and provides application of THADA in hyperlipidemia and cardiovascular metabolic diseases. THADA is used as a biomarker or target to prepare reagents for disease prediction, screening or diagnosis, and to prepare drugs for preventing or treating diseases. Inhibition or destruction of THADA function has the purposes of reducing blood cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, not affecting high-density cholesterol levels, reducing liver triglyceride deposition and liver steatosis, and improving atherosclerosis, and the effect is clear and effective and has no adverse reactions. The application provides a new biomarker and treatment target for hyperlipidemia and cardiovascular metabolic diseases, and has good practical application value and wide application prospect.

The invention belongs to the technical field of medical risk assessment, and provides a fibrosis metabolism related steatohepatitis risk assessment system. Comprising a data acquisition module configured to determine candidate prediction indexes; the primary screening module is configured to perform single-factor logistic regression analysis on the candidate prediction indexes to determine key prediction indexes of fibrosis metabolism related steatohepatitis; the secondary screening module is configured to screen out four independent predictive factors from key predictive indexes of fibrosis metabolism related steatohepatitis through stepwise multiple regression analysis; and the model training module is configured to train the constructed multi-factor logistic regression model based on the screened four independent predictive factors. According to the method, four indexes of aspartate transaminase, alanine transaminase, triglyceride and high-density lipoprotein cholesterol are integrated, a fibrosis MASH evaluation and prediction model for obese people is constructed, and the evaluation performance is better.

This invention discloses an oil composition with a balanced fatty acid ratio and lipid-lowering effects, and its applications. The oil composition comprises vegetable oil, probiotics, phospholipids from camellia seed cake, gelatin, and sodium alginate. It effectively reduces serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels while increasing high-density lipoprotein cholesterol levels, exhibiting a good lipid-lowering effect. Furthermore, when the oil composition is formulated into microcapsules, it exhibits good stability, encapsulation efficiency, and release rate. The oil composition also helps maintain the activity of probiotics, allowing for better preservation and efficacy. Based on this, this invention also provides a candy containing the oil composition, enriching the variety of products with lipid-lowering effects and promoting the development of lipid-lowering related products.

The application discloses a polysaccharide composition for treating hyperlipidemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing Vansant yellow, Inonotus hispidus and Sarcodon fuligineus and then extracting with water. The polysaccharide composition can inhibit the increase of body weight and blood sugar of hyperlipidemia mice, reduce fat vacuolization and fat index, reduce the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increase the content of high-density lipoprotein cholesterol, and regulate the composition and abundance of intestinal flora to improve the intestinal flora disorder phenomenon, and the effect is better than that of single polysaccharide, thereby providing a new direction for the treatment of auxiliary blood sugar reduction.

Method of lowering low-density lipoprotein cholesterol or preventing a cardiac event in a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent, involving administering to the subject a prophylactically effective amount of an RNAi agent. Also, a method of preventing development of atherosclerotic cardiovascular disease in a subject involving administering to the subject a prophylactically effective amount of an RNAi agent. Further, a method of treating a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent involving administering to the subject a therapeutically effective amount of an RNAi agent.

The invention relates to the technical field of detection reagent preparation, and discloses a stable oxidized low-density lipoprotein cholesterol detection kit and a preparation method thereof.The kit is composed of a component R1 and a component R2, the component R1 at least comprises a buffer solution, a sensitizer, a surfactant, a stabilizer, an anti-interference agent and a preservative, and the component R2 at least comprises a buffer solution, a sensitizer, a surfactant, a stabilizer, an anti-interference agent and a preservative; the component R2 at least comprises an ion buffer solution, a stabilizer, a sealing agent, an antibody-carboxyl microsphere conjugate and a preservative; the antibody-carboxyl microsphere conjugate is a conjugate of an oxidized low-density lipoprotein antibody and carboxyl microspheres. According to the formula of the oxidized low-density lipoprotein reagent composition, the reagent R1 and the reagent R2, the production cost is effectively reduced, the oxidized low-density lipoprotein reagent composition can be used on a full-automatic biochemical analyzer, the automation degree is high, compared with similar products, the oxidized low-density lipoprotein reagent composition has higher accuracy, repeatability and stability, and unexpected technical effects are achieved.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

This invention provides the use of RNA interferants that inhibit PCSK9 synthesis in prophylactic or therapeutic methods. [Solution] A method for reducing low-density lipoprotein cholesterol or preventing cardiac events in a subject having atherosclerotic cardiovascular disease or being at equivalent risk to atherosclerotic cardiovascular disease, comprising the step of administering a prophylactic effective amount of RNAi to the subject. Also, a method for preventing the onset of atherosclerotic cardiovascular disease in a subject, comprising the step of administering a prophylactic effective amount of RNAi to the subject. Furthermore, a method for treating a subject having atherosclerotic cardiovascular disease or being at equivalent risk to atherosclerotic cardiovascular disease, comprising the step of administering a therapeutic effective amount of RNAi to the subject.

The invention discloses a polysaccharide composition for treating chronic alcoholic liver injury and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is prepared by crushing phellinus linteus linteus, bolete, morchella and cordyceps militaris, mixing the crushed materials according to a mass ratio of 4: 2: 2: 2, performing water ultrasonic extraction, and performing hot water extraction. The polysaccharide composition can reduce fat vacuolation and hepatocyte swelling in the liver, inhibit expression of liver function related enzymes such as ALT and AST, improve secretion of blood fat such as total cholesterol, triglyceride and high-density lipoprotein cholesterol and reduce expression of inflammatory factors such as IL-1beta and TNF-alpha in the liver, and the effect of the polysaccharide composition is better than that of single polysaccharide. The polysaccharide composition can relieve liver injury caused by long-term drinking and achieve the effects of dispelling the effects of alcohol and protecting the liver.

The invention discloses a traditional Chinese medicine formula for preventing and treating body artery and blood vessel diseases, and relates to the technical field of pharmacy, in particular to a traditional Chinese medicine formula for preventing and treating body artery and blood vessel diseases, the traditional Chinese medicine composition is prepared from the following raw material medicines: 100g of radix puerariae, 100g of herba epimedii, 100g of herba leonuri, 50g of dioscorea panthaica, 50g of raw endothelium corneum gigeriae galli, 50g of fructus aurantii immaturus, 50g of rhizoma dioscoreae nipponicae, 50g of lumbricus and 50g of kapok leaves. Pharmacodynamic tests prove that compared with related traditional Chinese medicine prescriptions in the prior art, the traditional Chinese medicine composition can significantly reduce the intima-media thickness of blood vessels, reduce the area proportion of plaques, improve the blood vessel stenosis rate, and improve the curative effect. 0.05 in terms of prolonging thrombosis time, increasing microcirculation blood flow velocity, regulating blood lipid level (reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol), protecting vascular endothelial function (increasing the content of vascular endothelial relaxation factor NO and reducing endothelin ET level) and the like, and the pharmaceutical composition is superior to the prior art group (Plt: 0.05) in terms of prolonging thrombosis time, increasing microcirculation blood flow velocity, regulating blood lipid level (reducing total cholesterol, triglyceride, low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol).

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

This invention relates to compounds of Formula I and their isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, hydrates, prodrugs, and polymorphs. The compounds of Formula I can be used as inhibitors of proprotein convertase subtilisin 9 (PCSK9), effectively inhibiting PCSK9 activity and reducing the concentration of low-density lipoprotein cholesterol in plasma, and have good application prospects in the preparation of drugs for the treatment or prevention of cardiovascular diseases.

The present application relates to a kind of fish oil polypeptide composition for reducing blood fat and its application, belong to the field of biological medicine and functional food.The composition includes fish oil and pumpkin seed source active peptide C2-1 (molecular weight <3kDa), wherein active peptide accounts for 1-5% of the total weight of composition.Its preparation method includes: pumpkin seed protein complex zymolysis, ultrafiltration separation, anion exchange chromatography purification obtains C2-1 active peptide (KRGGRFL), then with fish oil homogenization into stable dispersion.The composition significantly reduces serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) by simultaneously inhibiting cholesterol esterase and lipase activity, and improves high-density lipoprotein cholesterol (HDL-C).Animal experiments show that its lipid-lowering effect is better than single fish oil, and is comparable to chemical drugs.The present application first realizes polypeptide-fish oil synergistic effect, provides safe and efficient new scheme for hyperlipidemia prevention and treatment.

The application discloses a method for constructing a hyperlipidemia-resistant rat model, and belongs to the technical field of experimental animal model construction. S1, basic population screening: abnormal lipid metabolism rats are selected, and the rats are fed with high-fat feed at the age of 4 weeks, and the feeding is continuously performed for 4 weeks; S2, blood lipid detection and preliminary screening: the animals are fasted for 12h, blood is taken from the submandibular vein, serum is separated by centrifugation at 3000r / min for 10min, and the total cholesterol, triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol contents are detected by using an automatic biochemical analyzer; S3, paired reproduction and subculture: 30 male rats and 30 female rats are selected, and the rats are paired for reproduction at a ratio of 1:1 to obtain F1 generation; S4, inbreeding and stabilization: the F2-F4 generation rats are repeatedly fed, detected, screened and paired for reproduction according to steps S1-S3, and the F4 generation hyperlipidemia-resistant rat model is obtained through inbreeding, and the technical effect of obtaining the hyperlipidemia-resistant rat model which is stable in phenotype and can be inherited and subcultured is achieved through the combination of hybridization screening and inbreeding.

The present application belongs to the technical field of medical risk assessment, and proposes a fibrosis metabolism related fatty hepatitis risk assessment system. It comprises: a data acquisition module configured to determine candidate prediction indicators; a primary screening module configured to perform single-factor logistic regression analysis on the candidate prediction indicators to determine key prediction indicators of fibrosis metabolism related fatty hepatitis; a secondary screening module configured to screen four independent prediction factors from the key prediction indicators of fibrosis metabolism related fatty hepatitis through stepwise multiple regression analysis; and a model training module configured to train a constructed multi-factor logistic regression model based on the four screened independent prediction factors. The present application integrates four indicators of aspartate aminotransferase, alanine aminotransferase, triglyceride and high-density lipoprotein cholesterol to construct a fibrosis MASH evaluation prediction model for obese people, which has better evaluation performance.

The invention discloses dry chemical test paper for detecting low-density lipoprotein cholesterol and application of the dry chemical test paper. The dry chemical test paper for detecting low-density lipoprotein cholesterol comprises a supporting layer (1), a blood filtering layer (2), a diffusion layer (3), a filtering layer (4), a reaction layer (5), absorbent paper (6), detection holes (7) and a bottom plate (8). The filter layer of the dry chemical test paper adopts a lateral chromatography layout, so that the contact time of a sample and the filter layer is prolonged, the reaction activity of non-LDL components is fully inhibited, the detection reliability and accuracy are improved, the dry chemical test paper innovatively and reversely utilizes an asymmetric membrane, an inverted structure is formed in the reaction process, and the detection sensitivity is improved. The side, far away from the surface of the reaction layer, of the filter layer is of a small-aperture asymmetric structure, and the side, close to the surface of the reaction layer, of the filter layer is of a large-aperture asymmetric structure, so that an LDL-c sample with higher concentration can be accurately measured.

The invention belongs to the technical field of medical chemistry, and particularly relates to a preparation method and application of eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester. According to the preparation method of the eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester, provided by the invention, 2-(3-indolyl) ethanol and eicosapentaenoic acid are used as raw materials, and lipase is added to react and synthesize the eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester. The eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester prepared by the preparation method disclosed by the invention has an excellent and comprehensive lipid-lowering effect, not only can effectively reduce the contents of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum, but also can effectively increase the level of high-density lipoprotein cholesterol. Meanwhile, the compound also has a strong direct blood vessel protection effect, can remarkably repair vascular endothelial dysfunction caused by high-fat diet and effectively recover endothelium-dependent vasodilatation capability, and is a safe and effective novel cardiovascular disease medicine.

A gene editing system comprising: (a) a gene editor fusion protein comprising a Cas protein and a deaminase, or a nucleic acid encoding the gene editor fusion protein, and (b) a hybrid guide nucleic acid comprising a spacer sequence, wherein the spacer sequence comprises at least one deoxyribonucleotide and a plurality of ribonucleotide is claimed. A 2’ hydroxyl group of a ribose on at least one ribonucleotide may be covalently linked to a methyl group (2’-OMe). The gene editing system for use in treating or preventing an atherosclerotic cardiovascular disease, or lowering blood low-density lipoprotein cholesterol (LDL-C) levels or lowering blood triglyceride levels is further claimed. [None]

The invention discloses a parabacteroides gore DZ001 strain with a cholesterol sulfation function and application of the parabacteroides gore DZ001 strain. The preservation number of the parabacteroides gore DZ001 is GDMCC No: 67376, and the preservation number of the parabacteroides gore DZ001 is H. The strain is separated from faeces of healthy people, a genome carries a sequence for coding sulfotransferase, cholesterol can be specifically catalyzed to generate cholesterol sulfate with higher water solubility, intestinal epithelium reabsorption is blocked, and faeces excretion is promoted. In-vitro experiments show that the strain has excellent cholesterol degradation capacity, gastrointestinal tract tolerance and safe gamma-hemolysis characteristics; in-vivo experiments prove that the traditional Chinese medicine composition can remarkably reduce serum total cholesterol and triglyceride levels of high-fat diet mice, increase high-density lipoprotein cholesterol, improve liver fatty degeneration and regulate blood glucose metabolism. The strain and viable bacteria, supernate or cell-free extract thereof can be widely applied to preparation of cholesterol-reducing health-care foods, medicines and animal feeds, and a new way is provided for prevention and treatment of hypercholesterolemia and related cardiovascular and cerebrovascular diseases.